Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer

Neoplasma

Volumn 57, Issue 3, 2010, Pages 228-233

  Zhang, Y W ^a   Miao, Y F ^a   Yi, J ^b   Geng, J ^a   Wang, R ^a   Chen, L B ^a  

^a NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Biomarker; DNA methylation; Non small cell lung cancer; SFRP 1

Indexed keywords

ANTINEOPLASTIC AGENT; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; MEMBRANE PROTEIN; MESSENGER RNA; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHINA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN METHYLATION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DNA METHYLATION; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; TRANSCRIPTION INITIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77954636165     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_03_228     Document Type: Article

References (36)

1. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J et al.: Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. doi:10.3322/canjclin.57.1.43
2. HENSCHKE CI, YANKELEVITZ DF, LIBBY DM, PASMANTIER MW, SMITH JP et al.: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-1771. doi:10.1056/NEJMoa060476
3. ANGLIM PP, ALONZO TA, LAIRD-OFFRINGA IA: DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008; 7: 81. doi:10.1186/1476-4598-7-81
4. BELINSKY SA, KLINGE DM, DEKKER JD, SMITH MW, BOCKLAGE TJ et al.: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005; 11: 6505-6511. doi:10.1158/1078-0432.CCR-05-0625
5. KIM H, KWON YM, KIM JS, LEE H, PARK JH et al.: Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004; 22: 2363-2370. doi:10.1200/JCO.2004.10.077
6. MAZIERES J, HE B, YOU L, XU Z, JABLONS DM.: Wnt signaling in lung cancer. Cancer Lett 2005; 222: 1-10. doi:10.1016/j.canlet.2004.08.040
7. NOJIMA M, SUZUKI H, TOYOTA M, WATANABE Y, MARUYAMA R et al.: Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007; 26: 4699-4713. doi:10.1038/ sj.onc.1210259
8. TAKAGI H, SASAKI S, SUZUKI H, TOYOTA M, MARUYAMA R et al.: Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol 2008; 43: 378-389. doi:10.1007/s00535-008-2170-0
9. ZOU H, MOLINA JR, HARRINGTON JJ, OSBORN NK, KLATT KK et al.: Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005; 116: 584-591. doi:10.1002/ijc.21045
10. SUZUKI H, TOYOTA M, CARAWAY H, GABRIELSON E, OHMURA T et al.: Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008; 98: 1147-1156. doi:10.1038/sj.bjc.6604259
11. ROMAN-GOMEZ J, CORDEU L, AGIRRE X, JIMENEZ-VELASCO A, SAN JOSE-ENERIZ E et al.: Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007; 109: 3462-3469. doi:10.1182/blood-2006-09-047043
12. SUZUKI M, SHIGEMATSU H, NAKAJIMA T, KUBO R, MOTOHASHI S et al.: Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007; 13: 6087-6092. doi:10.1158/ 1078-0432.CCR-07-0591
13. MARIST CJ, HOUSEMAN EA, CHRISTENSEN BC, EDDY K, BUENO R et al.: Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006; 66: 10621-10629. doi:10.1158/ 0008-5472.CAN-06-1687
14. SUZUKI H, GABRIELSON E, CHEN W, ANBAZHAGAN R, VAN ENGELAND M et al.: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-149. doi:10.1038/ng892
15. URAKAMI S, SHIINA H, ENOKIDA H, KAWAKAMI T, KAWAMOTO K et al.: Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006; 12: 2109-2116. doi:10.1158/1078-0432.CCR-05-2468
16. LIVAK KJ, SCHMITTGEN TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods 2001; 25: 402-408. doi:10.1006/ meth.2001.1262
17. SHI Y, HE B, YOU L, JABLONS DM: Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin 2007; 28: 1499-1504. doi:10.1111/j.1745-7254.2007.00692.x
18. WISSMANN C, WILD PJ, KAISER S, ROEPCKE S, STOEHR R et al.: WIF1, a component of the Wnt pathway, is downregulated in prostate, breast, lung, and bladder cancer. J Pathol 2003; 201: 204-212. doi:10.1002/path.1449
19. HRZENJAK A, TIPPL M, KREMSER ML, STROHMEIER B, GUELLY C et al.: Inverse correlation of secreted frizzledrelated protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol 2004; 204: 19-27. doi:10.1002/path.1616
20. FENG HAN Q, ZHAO W, BENTEL J, SHEARWOOD AM, ZEPS N et al.: Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett 2006; 231: 129-137. doi:10.1016/j.canlet.2005.01.026
21. LO PK, MEHROTRA J, D'COSTA A, FACKLER MJ, GARRETT-MAYER E et al.: Epigenetic Suppression of Secreted Frizzled Related Protein 1 (SFRP1) Expression in Human Breast Cancer. Cancer Biol Ther 2006; 5: 281-286.
22. HUANG J, ZHANG YL, TENG XM, LIN Y, ZHENG DL et al.: Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 2007; 7: 126. doi:10.1186/1471-2407-7-126
23. AWAKURA Y, NAKAMURA E, ITO N, KAMOTO T, OGAWA O: Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep 2008; 20: 1257-1263.
24. FUKUI T, KONDO M, ITO G, MAEDA O, SATO N et al.: Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in nonsmall-cell lung cancer. Oncogene 2005; 24: 6323-6327. doi:10.1038/ sj.onc.1208777
25. SHIH YL, HSIEH CB, LAI HC, YAN MD, HSIEH TY et al.: SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer 2007; 121: 1028-1035. doi:10.1002/ijc.22750
26. CHUNG MT, LAI HC, SYTWU HK, YAN MD, SHIH YL et al.: SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol 2009; 112: 646-653. doi:10.1016/ j.ygyno.2008.10.026
27. LICCHESI JD, WESTRA WH, HOOKER CM, MACHIDA EO, BAYLIN SB et al.: Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008; 29: 895-904. doi:10.1093/carcin/bgn017
28. JAHR S, HENTZE H, ENGLISCH S, HARDT D, FACKELMAYER FO et al.: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.
29. HSU HS, CHEN TP, HUNG CH, WEN CK, LIN RK et al.: Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007; 110: 2019-2026. doi:10.1002/cncr.23001
30. FUJIWARA K, FUJIMOTO N, TABATA M, NISHII K, MATSUO K et al.: Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005; 11: 1219-1225.
31. BELINSKY SA, GRIMES MJ, CASAS E, STIDLEY CA, FRANKLIN WA et al.: Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007; 96: 1278-1283. doi:10.1038/ sj.bjc.6603721
32. WANG Y, YU Z, WANG T, ZHANG J, HONG L et al.: Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007; 56: 289-294. doi:10.1016/j.lungcan.2006.12.007
33. VEECK J, NIEDERACHER D, AN H, KLOPOCKI E, WIESMANN F et al.: Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006; 25: 3479-3488. doi:10.1038/ sj.onc.1209386
34. TOYOTA M, SUZUKI H, YAMASHITA T, HIRATA K, IMAI K et al.: Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009; 100: 787-791. doi:10.1111/j.1349-7006.2009.01095.x
35. WANG Y, ZHANG D, ZHENG W, LUO J, BAI Y et al.: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 2008; 112: 1325-1336. doi:10.1002/cncr.23312
36. RAUCH TA, ZHONG X, WU X, WANG M, KERNSTINE KH et al.: High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 2008; 105: 252-257. doi:10.1073/pnas.0710735105